Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018)

Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Dawood, 2010, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review, J Clin Oncol Off J Am Soc Clin Oncol, 28, 92, 10.1200/JCO.2008.19.9844 Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol Off J Am Soc Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173 Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383 Cameron, 2017, 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial, Lancet Lond Engl, 389, 1195, 10.1016/S0140-6736(16)32616-2 Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366, 109, 10.1056/NEJMoa1113216 Swain, 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 372, 724, 10.1056/NEJMoa1413513 Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124 Cardoso, 2018, 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†, Ann Oncol Off J Eur Soc Med Oncol, 29, 1634, 10.1093/annonc/mdy192 Burstein, 2019, Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019, Ann Oncol Off J Eur Soc Med Oncol, 30, 1541, 10.1093/annonc/mdz235 Pérol, 2019, The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME), BMJ Open, 9, 10.1136/bmjopen-2018-023568 Vaz-Luis, 2019, UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO), ESMO Open, 4, 10.1136/esmoopen-2019-000562 Cardoso, 2016, ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3), Ann Oncol, mdw544 Bachelot, 2019, Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE), Ann Oncol Off J Eur Soc Med Oncol, 30, 766, 10.1093/annonc/mdz061 Urruticoechea, 2017, Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy, J Clin Oncol Off J Am Soc Clin Oncol, 35, 3030, 10.1200/JCO.2016.70.6267 Perez, 2019, Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE, Cancer, 125, 3974, 10.1002/cncr.32392